Fundraising Fox
/Companies
Sign in

Abivax

Paris, FR · Founded 2013 · 7 known investors

Find your way into Abivax

Sign up to see every warm intro you have to Abivax

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Abivax team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

BiotechHealthtechMedical Devices

Founders & leadership

MDMarc de Garidel
Marc de GaridelCEOHe previously led CinCor Pharma, AZTherapies and Corvidia Therapeutics as chief executive, and spent years at Ipsen, serving as Chairman and CEO from 2010 to 2016 and as Chairman thereafter. He joined Abivax in 2023, initially as CEO and interim chairman.

Investors · 7

Claret Capital Partnerslisted by Claret Capital PartnersLondon

How we know: Claret Capital Partners's portfolio page · Not right? Tell us

Medicxilisted by MedicxiLondon

How we know: Medicxi's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Truffle Capitallisted by Truffle CapitalParis · $5M – $15M

How we know: Truffle Capital's portfolio page · Not right? Tell us

Morgan StanleyreportedPurchase

How we know: press coverage · Not right? Tell us

Related companies · 7

DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
ImvaxImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.

Companies working in the same space as Abivax.

In the news

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCcnbc.com · Jul 2026Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCcnbc.com · Jul 2026

Frequently asked questions

What does Abivax do?
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
Who are Abivax's investors?
Abivax's investors include Andera Partners, Claret Capital Partners, Medicxi, Samsara BioCapital, Sofinnova Partners, Truffle Capital, Morgan Stanley.
Where is Abivax headquartered?
Abivax is headquartered in Paris, FR.